Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2010-11-08 Report Publication Anno…
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC AG: Q3 2010 Results Conference Call 11 November 2010
Report Publication Announcement Classification · 99% confidence The document explicitly announces that 4SC AG will host a 'Q3 2010 Results Conference Call' on November 11, 2010, providing dial-in numbers, time, and conference ID. This content is the invitation and details for a conference call where results will be discussed, which perfectly matches the definition of a Call Transcript (CT) source material, even though this document is the announcement of the call, not the transcript itself. However, among the provided options, 'Call Transcript (Code: CT)' is the most appropriate classification for material directly related to an earnings/results conference call, as there is no specific code for 'Conference Call Announcement'. Given the content is entirely focused on setting up the call to discuss Q3 results, CT is the best fit over a general RNS or RPA.
2010-11-08 English
4SC AG: 4SC's Vidofludimus Meets Primary Endpoint with Excellent Response Rate in IBD Trial
Regulatory Filings Classification · 99% confidence The document is titled 'News Details' and is explicitly marked as 'Ad-hoc' with a date of '4 November 2010'. It announces positive preliminary results from a Phase IIa study ('ENTRANCE study met its primary endpoint'). It also mentions hosting a 'conference call at 4pm CET (10am EST) today to inform about the preliminary results of the study.' This structure—a brief announcement of results followed by details of a conference call—is characteristic of an Earnings Release (ER) or a general news announcement. Since it is a specific, time-sensitive announcement of preliminary clinical trial results, it fits best under the 'Earnings Release' category, which often covers key operational/scientific milestones for biotech/pharma companies, or potentially 'Regulatory Filings' (RNS) as a general news item. Given the focus on announcing key preliminary results and scheduling a call to discuss them, ER is a strong fit, although it is not strictly quarterly earnings. However, the document is a direct, immediate release of material information, which aligns closely with the function of an ER or a major press release. Since 'ER' covers periodical financial results, and this is a major operational/scientific result announcement, I will classify it as a general news release/announcement, which defaults to 'RNS' if no other category fits perfectly. Given the context of announcing key operational/scientific milestones (drug trial results) and scheduling a call, it functions as a major news release. Since there is no specific 'Clinical Trial Result Announcement' code, and it is not a full report (10-K, IR), nor a presentation (IP), the most appropriate general regulatory/news category is RNS.
2010-11-04 English
4SC Announces Initial Phase II Data from the SAPHIRE Study with Resminostat at the 8th International Symposium on Hodgkin Lymphoma
Regulatory Filings Classification · 99% confidence The document is a press release dated October 26, 2010, from 4SC AG announcing initial Phase II data from the SAPHIRE study regarding their drug resminostat at a medical symposium. It details clinical results (safety, tolerability, efficacy), study design (Simon two-stage), and includes commentary from the lead investigator and the Chief Development Officer. This content structure—a formal announcement of research findings and clinical trial progress, often released to the public and investors simultaneously—is characteristic of an Earnings Release (ER) or a general corporate/research update. Since it is a specific announcement of research results rather than a comprehensive quarterly/annual financial report (10-K or IR), and it is not a transcript (CT) or a formal investor presentation (IP), the most fitting category for a focused, time-sensitive announcement of key operational/research milestones is Earnings Release (ER), as these often include operational highlights alongside any financial reporting, or it could be classified as a Regulatory Filing (RNS) if it were purely regulatory. Given the focus on presenting clinical data and study progression, it functions as a key operational update, which often falls under the umbrella of an ER or a general news release. Since there is no specific 'Research Update' code, and it is a detailed announcement of results rather than just a link to a report (RPA), ER is the closest fit for a significant, periodic operational disclosure, although RNS is a strong secondary candidate as a general news release.
2010-10-26 English
4SC Presents Initial Data from the Resminostat (4SC-201) Phase II SHELTER study in Hepatocellular Carcinoma (HCC)
Regulatory Filings Classification · 99% confidence The document is a news release dated September 17, 2010, announcing that 4SC AG will present initial clinical data from the Phase II SHELTER study for their drug resminostat at a medical symposium ('Viszeralmedizin 2010'). It details the study design, initial safety/tolerability data, and includes commentary from company executives and the lead investigator. This content is characteristic of an announcement regarding clinical trial progress or scientific presentation, which is not explicitly covered by the primary financial filing types (10-K, IR, ER, etc.). Since it is a corporate news item detailing scientific/development progress and does not fit into specific categories like Earnings Release (ER), Interim Report (IR), or Management Discussion (MDA), it falls best under the general regulatory/corporate announcement category, RNS (Regulatory Filings), as a fallback for miscellaneous corporate news that isn't strictly financial reporting or a specific corporate action announcement (like dividend or management change). The document length is substantial (over 10,000 characters), indicating it is the full announcement, not just a brief link to a report (which would suggest RPA).
2010-09-17 English
4SC Provides Enrolment Update for Phase IIb Rheumatoid Arthritis Study with Vidofludimus (4SC-101)
Regulatory Filings Classification · 96% confidence The document is a press release dated September 16, 2010, providing an update on the enrollment status and expected timeline for preliminary results of a Phase IIb clinical trial (COMPONENT study) for the drug Vidofludimus in Rheumatoid Arthritis patients. It contains operational updates, contact information, and background on the disease and the drug. It is not a formal regulatory filing like a 10-K, a comprehensive financial report (IR), an earnings release (ER), or a specific legal/governance document. Since it is a general corporate announcement regarding business progress that doesn't fit the highly specific categories (like DIV, CAP, MANG, etc.), it falls best under the general 'Regulatory Filings' or 'Miscellaneous' category. Given the provided options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the most appropriate classification for a standard corporate news update that isn't a core financial report or specific event announcement.
2010-09-16 English
4SC to Present at the UBS Global Life Sciences Conference 2010
Regulatory Filings Classification · 100% confidence The document is a short news release dated September 13, 2010, announcing that the CEO of 4SC AG will be presenting at the UBS Global Life Sciences Conference on September 22, 2010. It contains company background, contact information, and a legal disclaimer. It is not a full financial report (10-K, IR, ER), a proxy statement (DEF 14A), or a formal regulatory filing detailing a specific event like a dividend or share transaction. Since it is an announcement about a future event (a presentation) and does not fit neatly into the other specific categories, it is best classified as a general Regulatory Filing or Regulatory Announcement, which corresponds to the RNS code, as it is disseminated via the DGAP News-Service.
2010-09-13 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.